Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Investor Presentation (March 2023)

41 slides from Day One Biopharmaceuticals's investor presentation, Mar 6, 2023

  1. Slide 1: Targeted Therapies for People of All Ages

    Day One Biopharmaceuticals Day One Biopharmaceuticals Targeted Therapies for People of All Ages March 2023

  2. Slide 2: Disclaimer

    Disclaimer This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some

  3. Slide 3: Cancer Drug Development for People of All Ages

    Cancer Drug Development for People of All Ages Growing Portfolio and Runway Beyond Clinical Milestones Tovorafenib (DAY101) Lead Program Mission That Creates Value Day One’s mission is to help children with cancer, from day one and every day after Develop medicines for genomically-defined cancers Es

  4. Slide 4: A Senior Team with Deep Experience in Pediatric and Adult Oncology

    Jaa Roberson Chief People Officer Head of Human Resources at Bellicum Pharmaceuticals; Human Resources Roles at Achaogen, Roche/Genentech Davy Chiodin, PharmD Chief Development Officer VP Regulatory Science, Acerta/AZ; Global Regulatory Leader, Pediatric Oncology, Roche/Genentech A Senior Team with

  5. Slide 5: Our Pipeline

    Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/tovorafenib) Our Pipel

  6. Slide 6: Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

    Day One Biopharmaceuticals Tovorafenib (DAY101) Type II Pan-RAF Inhibitor

  7. Slide 7: Pediatric Low-Grade Gliomas (pLGG)

    Pediatric Low-Grade Gliomas (pLGG) Day One Biopharmaceuticals Despite being the most common brain tumor in children, there are no approved agents and no standard-of-care for the majority of patients with relapsed/progressive disease1,2 ~70% of patients will require systemic therapy Patients have a h

  8. Slide 8: Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations

    Tovorafenib (DAY101) Inhibits Both BRAF Fusions and BRAF V600 Mutations Day One Biopharmaceuticals Tovorafenib (DAY101) is an investigational, oral, selective, CNS-penetrant, type II pan-RAF inhibitor that was designed to inhibit both monomeric and dimeric RAF kinase Activity in tumors driven by bot

  9. Slide 9: The Current pLGG Treatment Paradigm

    The Current pLGG Treatment Paradigm Reflects the Unrelenting Nature of this Chronic Brain Tumor Day One Biopharmaceuticals Source: Physician Interviews, Bandopadhayay et al. Pediatric Blood Cancer. 2014; Sievert and Fischer. J Child Neurol. 2009; ClearView Analysis. GTR: Gross Total Resection 1Molec

  10. Slide 10: Pivotal Phase Trial of Tovorafenib in Relapsed or Progressive pLGG (FIREFLY-1)

    Pivotal Phase 2 Trial Of Monotherapy Tovorafenib (DAY101) in Relapsed or Progressive pLGG (FIREFLY-1) Day One Biopharmaceuticals Primary endpoint: ORR based on RANO criteria, assessed by blinded independent central review Secondary endpoints: ORR by RAPNO criteria; PFS; safety Three arm, open-label,

  11. Slide 11: FIREFLY-1 Baseline Patient Characteristics

    FIREFLY-1 Baseline Patient Characteristics Day One Biopharmaceuticals Characteristic Topline Data Arm 1 (N=77) Median age, years (range) 8 (2-21) BRAF alteration, n (%) BRAF V600E BRAF Fusion† 13 (17) 64 (83) Median number of lines of prior therapy (range) 3 (1-9) Prior MAPK pathway targeted therapy

  12. Slide 12: Topline Data from Ongoing Pivotal Phase FIREFLY-1 Trial

    Topline Data from Ongoing Pivotal Phase 2 FIREFLY-1 Trial Day One Biopharmaceuticals Sep 28, 2022 data cutoff. CR, complete response. PR, partial response. SD, stable disease. The primary endpoint of the FIREFLY-1 trial is overall response rate (ORR) by Response Assessment for Neuro-Oncology (RANO)

  13. Slide 13: Incidence and Prevalence of BRAF-altered pLGG in the U.S.

    ~26,000 Estimated Prevalence Incidence and Prevalence of BRAF-altered pLGG in the U.S. Day One Biopharmaceuticals 1. US Census; 2 CBTRUS, Qaddoumi et al 2009, Schreck et al 2019, ClearView Analysis; 3 SEER US complete prevalence counts of patients aged under 25 with Brain and Other Nervous Systems t

  14. Slide 14: FIREFLY-2/LOGGIC Pivotal Phase Trial in Newly Diagnosed pLGG

    Day One Biopharmaceuticals FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG

  15. Slide 15: FIREFLY-2/LOGGIC Pivotal Phase Trial in Newly Diagnosed pLGG

    FIREFLY-2/LOGGIC Pivotal Phase 3 Trial of Tovorafenib (DAY101) in Newly Diagnosed pLGG Day One Biopharmaceuticals Primary endpoint: ORR based on RANO criteria, assessed by blinded independent central review The ORR primary analysis is expected to occur ~12 months after the last patient randomized Ke

  16. Slide 16: FIREFLY-2/LOGGIC Collaboration and Sites

    FIREFLY-2/LOGGIC: Pivotal Phase 3 Study Of Tovorafenib (DAY101) In Newly Diagnosed pLGG Day One Biopharmaceuticals Collaboration between Day One and the LOGGIC consortium, internationally recognized experts in pLGG research Coupled with the LOGGIC-CORE molecular diagnostic program Worked jointly on

  17. Slide 17: Our Pipeline

    Product Candidate Indication Preclinical Phase 1 Phase 2 Phase 3 Recent & Anticipated Milestones Tovorafenib (DAY101) Type II Pan-RAF Inhibitor Relapsed pLGG Frontline pLGG RAF-altered solid tumors2 (monotherapy) Pimasertib MEK 1/2 Inhibitor MAPK-altered solid tumors3 (Combo w/tovorafenib) Our Pipel

  18. Slide 18: Next-generation RAF Inhibitors Address Adult Cancers with RAF Wild-type Fusions

    Next-generation RAF Inhibitors are Unique in Their Ability to Address Adult Cancers Associated with RAF Wild-type Fusions Day One Biopharmaceuticals Botton T et al, Cell Reports, 2019 LY3009120: Lilly pan-RAFi Lifirafenib: Beigene pan-RAF/EGFRi CCT196969: CRUK RAF ”paradox breaker” BRAFwt fusion mix

  19. Slide 19: Phase Study of Monotherapy Tovorafenib in Solid Tumors (FIRELIGHT-1)

    Phase 2 Study of Monotherapy Tovorafenib (DAY101) in Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Abbreviations: ORR, objective response rate; QW, once weekly ; PO, by mouth; BRAF, B-Raf proto-oncogene. Umbrella master study – DAY101-102 (main protocol) DAY101 and MAPK pathway aberration, S

  20. Slide 20: Activity of Tovorafenib in SNX8:BRAF Fusion Spindle Cell Sarcoma

    Activity of Tovorafenib (DAY101) in SNX8:BRAF Fusion Spindle Cell Sarcoma Day One Biopharmaceuticals A male child spindle cell sarcoma, 5-years of age at diagnosis Data cut off: September 30, 2021 Months -30 -24 -18 -12 -6 0 6 Diagnosis BRAF fusion (FISH) CR PD CR Gemcitabine, docetaxel Proton radio

  21. Slide 21: Scientific Rationale for Combining Tovorafenib with MAPK Pathway Inhibitors

    Strong Scientific Rationale for Combining Tovorafenib (DAY101) with Additional MAPK Pathway Inhibitors Day One Biopharmaceuticals Type II RAFi + MEKi Type II RAFi + SHP2i Type II RAFi + SHP2i MEKi or Type II RAFi + SHP2i MEKi or KRAS - G12Ci or Potential combinations BRAF non-V600 BRAF or CRAF WT fu

  22. Slide 22: Pimasertib MEK1/2 Inhibitor

    Day One Biopharmaceuticals Pimasertib MEK1/2 Inhibitor

  23. Slide 23: Pimasertib: Investigational Allosteric MEK1/2 Inhibitor

    Pimasertib: Investigational Allosteric MEK1/2 Inhibitor with Demonstrated Activity in MAPK-driven Solid Tumors Day One Biopharmaceuticals Pimasertib is an investigational orally-bioavailable, selective, non-competitive MEK1/2 inhibitor in-licensed from Merck KGaA in February 2021 Extensive non-clini

  24. Slide 24: Vertical MAPK Pathway Inhibition with Tovorafenib and Pimasertib

    Vertical MAPK Pathway Inhibition with Tovorafenib (DAY101) and Pimasertib May Unlock Potential Synergy for Adult Solid Tumors Day One Biopharmaceuticals Mechanistic model for vertical MAPK pathway inhibition (modified from Yen et al. Cancer Cell, 2018) . DAY101 + MEK inhibitor is synergistic in KRAS

  25. Slide 25: Tovorafenib / Pimasertib Combination in Solid Tumors (FIRELIGHT-1)

    Tovorafenib (DAY101) / Pimasertib Combination to be Evaluated in Solid Tumors (FIRELIGHT-1) Day One Biopharmaceuticals Abbreviations: BOIN, Bayesian Optimal Interval Design; BRAF, B-Raf proto-oncogene, serine/threonine kinase; MAPK, mitogen-activated protein kinase; NRAS, neuroblastoma rat sarcoma v

  26. Slide 26: Summary

    Day One Biopharmaceuticals Summary

  27. Slide 27: Financial Summary: DAWN

    Financial Summary: DAWN Day One Biopharmaceuticals $ Millions Twelve Months Ended 12/31/22 Twelve Months Ended 12/31/21 R&D Expense $85.6 $43.6 G&A Expense $61.3 $29.2 Net Loss $142.2 $72.8 FIREFLY-1: Pivotal Phase 2 clinical trial of tovorafenib (DAY101) Topline results presented in January 2023 Pr

  28. Slide 28: Next Steps

    Next Steps Day One Biopharmaceuticals FIREFLY-1 Present NDA data set at medical meeting in Q2 2023 Pre-NDA meeting and NDA submission planned for 1H 2023 FIREFLY-2 Advance tovorafenib as a front-line therapy for patients newly diagnosed with pLGG Commercial Continue investment in market and launch p

  29. Slide 29: Appendix

    Appendix Day One Biopharmaceuticals

  30. Slide 30: FIREFLY-1 Baseline Characteristics

    FIREFLY-1 Baseline Characteristics Day One Biopharmaceuticals Characteristic Arm 1 (N=25) Median age, years (range) 8 (3-18) Sex, n (%) Male Female 13 (52) 12 (48) Race, n (%) Black or African American Asian White Other* 1 (4) 2 (8) 15 (60) 7 (28) Karnofsky/Lansky performance status, n (%) 50-70 80-

  31. Slide 31: Tumor Response to Tovorafenib for RANO-Evaluable Patients

    Tumor Response To Tovorafenib (DAY101) For All Patients With RANO-Evaluable Lesions (n=22)* Day One Biopharmaceuticals Response (IRC) RANO Evaluable N=22* ORR (95% CI) 64% (41-83) BRAF fusion (n=20) 60% BRAF V600E (n=2) 100% CBR# 91% Best overall response PR (13/22) 59% uPR (1/22) 5% SD (6/22) 27% A

  32. Slide 32: Duration of Tovorafenib Therapy

    Duration of Tovorafenib (DAY101) Therapy For All Patients with RANO-Evaluable Lesions (n=22) Day One Biopharmaceuticals Apr 14, 2022 data cutoff. 17/22 patients remain on therapy All responders remain on treatment

  33. Slide 33: Individual Patient Tumor Change From Baseline

    Individual Patient Tumor Change From Baseline (n=22 RANO-Evaluable By Blinded Independent Central Review) Day One Biopharmaceuticals PR PD SD CR Percent change from baseline (%) Months Apr 14, 2022 data cutoff. RANO PD = ≥+25% change from baseline; RANO SD = <+24% to > -50% change from baseline; RAN

  34. Slide 34: Tovorafenib Safety Data for the First Enrolled Patients

    Tovorafenib (DAY101) Safety Data For the First 25 Enrolled Patients (TEAEs ≥25% Any Grade) Day One Biopharmaceuticals Preferred term, n (%) Treatment-emergent AEs Treatment-related AEs Any grade Grade ≥3 Any grade Grade ≥3 Blood creatine phosphokinase increased 20 (80) 2 (8) 18 (72) 2 (8) Hair color

  35. Slide 35: Key Takeaways

    Key Takeaways Day One Biopharmaceuticals Encouraging initial efficacy data from FIREFLY-1 for pediatric patients with recurrent or progressive LGG harboring BRAF fusion or BRAF V600 mutation, for whom there is no standard-of-care and no approved agents for the majority of patients 64% ORR and 91% cl

  36. Slide 36: Case Study: KIAA1549-BRAF Fusion Optic Pathway Glioma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Optic Pathway Glioma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. PR (-58%) and improvement in vision reported

  37. Slide 37: Case Study: KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In KIAA1549-BRAF Fusion Posterior Fossa Pilocytic Astrocytoma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. Baseline After 6 cycles Afte

  38. Slide 38: Case Study: BRAF V600E Mutation Deep Midline Astrocytoma

    Case Study: Activity Of Tovorafenib (DAY101) In BRAF V600E Mutation Deep Midline Astrocytoma Day One Biopharmaceuticals Apr 14, 2022 data cutoff. Tovorafenib is an investigational agent. Safety and efficacy have not been established by any health authority. Baseline After 6 cycles After 3 cycles Tum

  39. Slide 39: Results from Independent Radiology Review of PNOC014

    Results from Independent Radiology Review of PNOC014 Day One Biopharmaceuticals RAPNO: Response assessment for pediatric neuro-oncology (exploratory) RANO: Response assessment for neuro-oncology (FDA standard) Volumetric image analysis (exploratory) Best response from baseline Date of data cutoff: 0

  40. Slide 40: Multiple Rapid, Deep and Durable Responses in PNOC014

    Multiple Rapid, Deep and Durable Responses Observed following Initiation of Tovorafenib (DAY101) Treatment of pLGG Patients in PNOC014 Day One Biopharmaceuticals Date of data cutoff: 02 JAN 2020 Adapted from Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020 Fangusaro J et al. Lancet Oncol 2019

  41. Slide 41: Drug-related Adverse Events for Tovorafenib in PNOC014

    Drug-related Adverse Events Observed for Tovorafenib (DAY101) in PNOC014 Showed Favorable Safety and Tolerability Profile in pLGG Day One Biopharmaceuticals Date of DAY101 data cutoff: 02 JAN 2020; Wright K et. al. Neuro Oncology Abstract CTNI-19. 2020; Fangusaro J et al. Lancet Oncol 2019 Toxicitie

Day One Biopharmaceuticals — Investor Presentation (March 2023) on 6ix